Tumor growth is stimulated by muscarinic receptor agonism: Role of autoantibodies in breast cancer patients

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 208-215

  Sales, María Elena ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Autoantibodies; Autoantigens; Cells proliferation; Inositol monophosphate; MCF 7 T1N0Mx breast tumors; Muscarinic receptors; Nitric oxide synthase; Phospholipase C 2; Protein kinase c; Tumor progression

Indexed keywords

AUTOANTIBODY; CARBACHOL; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR;

ANTIBODY RESPONSE; AUTOIMMUNITY; B LYMPHOCYTE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CELL CYCLE ARREST; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; RECEPTOR UPREGULATION; REVIEW; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

EID: 84866419407     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/187152212802001839     Document Type: Review

References (44)

1. Hwu, P. Treating cancer by targeting the immune system. N. Engl. J. Med., 2010, 363, 779-781.
2. Burnet, F. The concept of immunological surveillance. Prog. Exp. Tumor Res., 1970, 13, 1-27.
3. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011, 331, 1565-1570.
4. Khong, H.T.; Restifo, N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol., 2002, 3, 999-1005.
5. Sheng, K.C.; Wright, M.D.; Apostolopoulos, V. Inflammatory mediators hold the key to dendritic cell suppression and tumor progression. Curr. Med. Chem., 2011, 18, 5507-5518.
6. Ryan, S.O.; Turner, M.S.; Gariépy, J.; Finn, O.J. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res., 2010, 70, 5788-5796.
7. Abken, H.; Hombach, A.; Heuser, C.; Kronfeld, K.; Seliger, B. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol., 2002, 23, 240-245.
8. Nelson, B.H. CD20+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol., 2010, 185, 4977-4982.
9. Kim, S.; Fridlender, Z.G.; Dunn, R.; Kehry, M.R.; Kapoor, V.; Blouin, A.; Kaiser, L.R.; Albelda, S.M. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J. Immunother., 2008, 31, 446-457.
10. Stauss, H.J. Benign autoimmunity to combat malignancy. Clin. Exp. Immunol., 2001, 125, 1-2.
11. Torchilin, V.; Iakoubov, L.; Estrov, Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol., 2001, 22, 424-427.
12. Bazhin, A.V.; Shifrina, O.N.; Savchenko, M.S.; Tikhomirova, N.K.; Goncharskaia, M.A.; Gorbunova, V.A.; Senin, I.I.; Chuchalin, A.G.; Philippov, P.P. Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer without a loss of vision. Lung Cancer, 2001, 34, 99-104.
13. DiLillo, D.J.; Matsushita, T.; Tedder, T.F. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. N.Y. Acad. Sci., 2010, 1183, 38-57.
14. Armanasco, E.; Azar, M.E.; Gonzalez, E.; Cresta Morgado, C.; Montoya, D.; Noblia, C.; Ipiña, M. In: Pautas en Oncología. Diagnóstico, tratamiento y seguimiento del cáncer. Tumores de mama; Roth Berta, Ed.; Inst. de Oncologia A.H. Roffo, UBA: Buenos Aires, 2010, Vol. 1, pp. 10-46.
15. DeNardo, D.G.; Coussens, L.M. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res., 2007, 9, 212. http://breastcancer-research.com/content/9/4/212
16. Hansen, M.; Ostenstad, B.; Sioud, M. The tumor infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc. Natl. Acad. Sci. USA, 2001, 98, 12659-12664.
17. Fernandez Madrid, F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett., 2005, 230, 187-198.
18. van Coppen, C.J.; Kaiser, V. Regulation of muscarinic acetylcholine receptors signaling. Pharmacol. Ther., 2003, 98, 197-200.
19. Eglen, RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton. Autacoid Pharmacol., 2006, 26, 219-233.
20. Paleari, L.; Grozio, A.; Cesario, A.; Russo, P. The cholinergic system in cancer. Sem. Cancer Biol., 2008, 18, 211-217.
21. Español, A.; Eiján, A.; Mazzoni, E.; Davel, L.; Jasnis, M.A.; Sacerdote de Lustig, E.; Sales, M.E. Nitric Oxide Synthase, Arginase and Cyclooxygenase are Involved in Muscarinic Receptors Activation in Different Murine Mammary Adenocarcinoma Cell Lines. Int. J. Mol. Med., 2002, 9, 651-657.
22. Rimmaudo, L.; de la Torre, E.; Sacerdote de Lustig, E.; Sales, M.E. mAchR are involved in murine mammary adenocarcinoma cells LMM3 proliferation and angiogenesis. Biochem. Biophys. Res. Commun., 2005, 334, 1360-1365.
23. Español, A.; de la Torre, E.; Fiszman, G.; Sales, M.E. Role of non-neuronal cholinergic system in breast cancer progression. Life Sci., 2007, 80, 2281-2285.
24. Fiszman, G.L.; Sales M.E. Antibodies against muscarinic receptors in breast cancer: agonizing tumor growth. Curr. Immunol. Rev., 2008, 4, 176-182.
25. Fiszman, G.L.; Middonno, M.C.; de la Torre, E.; Farina, M.; Español, A.J.; Sales, M.E. Activation of muscarinic cholinergic receptors induces MCF-7 cells proliferation and angiogenesis by stimulating nitric oxide synthase activity. Cancer Biol. Ther., 2007, 6, 1106-1113.
26. Jiménez, E.; Montiel, M. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J. Cell. Physiol., 2005, 204, 678-686.
27. Grando, S.A. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity., 2012, 45, 7-35.
28. Goin, J.C.; Nathanson, N. Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells: regulation of receptor down-regulation by heterodimerization. J. Biol. Chem., 2006, 281, 5416-5425.
29. Park, P.S.; Wells, J. Oligomeric potential of the M2 muscarinic cholinergic receptor. J. Neurochem., 2004, 90, 537-548.
30. Zhang, J.Y., Zhu, W., Imai, H.; Kiyosawa, K.; Chan, E.K.; Tan, E.M. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin. Exp. Immunol., 2001, 125, 3-9.
31. Lu, P.; Zhu, X.Q.; Xu, Z.L.; Zhou, Q.; Zhang, J.; Wu, F. Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery, 2009, 145, 286-293.
32. Morton, B.A.; Ramey, W.G.; Paderon, H.; Miller R.E. Monoclonal antibody defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer. Cancer Res., 1986, 46, 2121-2126.
33. Wernicke, M. Quantitative morphologic assessment of immunoreactivity in regional lymph nodes of patients with carcinoma of the breast. Surg. Gynecol. Obstet., 1975, 140, 919-924.
34. Fiszman, G.; Cattaneo, V.; de la Torre, E.; Español, A.; Colombo, L.L.; Sacerdote de Lustig, E.; Sales, M.E. Muscarinic receptors autoantibodies purified from mammary adenocarcinoma bearing mice sera stimulate tumor progression. Int. Immunopharmac., 2006, 6, 1323-1330.
35. Fiszman, G.; Cattaneo, V.; de la Torre, E.; Colombo, L.; Middonno, M.C.; Sacerdote de Lustig, E.; Sales, M.E. Autoanticuerpos contra receptores muscarínicos en cáncer de mama. Química Viva, 2005, 4, 1-17.
36. Negroni, M.P.; Fiszman, G.L.; Azar, M.E.; Cresta Morgado, C.; Español, A.J.; Pellegrina, L.T.; de la Torre, E. Sales, M.E. mAChR activity is modulated by auto-antibodies from breast cancer patients in MCF-7 cells. J. Clin. Immunol., 2010, 30, 474-484.
37. Wen, Y.; Mancino, A.; Pashov, A.; Whitehead, T.; Stanley, J.; Kieber-Emmons, T. Antigen binding of human IgG Fabs mediates ERK-associated proliferation of human breast cancer cells. DNA Cell. Biol., 2005, 24, 73-84.
38. You, J.; Mi, D.; Zhou, X.; Qiao, L.; Zhang, H.; Zhang, X.; Ye, L. A positive feedback between activated extracellularly regulated kinase and cyclooxygenase/lipoxygenase maintains proliferation and migration of breast cancer cells. Endocrinology, 2009, 150, 1607-1617.
39. Alvarez-Breckenridge, C.A.; Waite, K.A.; Eng, C. PTEN regulates phospholipase D and phospholipase C. Hum. Mol. Gen., 2007, 16, 1157-1163.
40. Lancaster, J.R.; Xie, K. Tumors face NO problems? Cancer Res., 2006, 66, 6459-6462.
41. Schulze, W.; Kunze, R.; Wallukat, G. Pathophysiological role of autoantibodies against G-protein-coupled receptors in the cardiovascular system. Exp. Clin. Cardiol., 2005, 10, 170-172.
42. Sales, M.E.; Español, A.J.; Sterin-Borda, L.; Borda, E.; de Bracco, M.M. Protein kinase C regulates NO-cGMP pathway in muscarinic receptor activation by HIV+-IgA. Int. J. Mol. Med., 1999, 3, 633-637.
43. Hernandez, C.C.; Nascimento, J.H.; Chaves, E.A.; Costa, P.C.; Masuda, M.O.; Kurtenbach, E.; Campos, D.E.; Carvalho, A.C.; Gimenez, L.E. Autoantibodies enhance agonist action and binding to cardiac muscarinic receptors in chronic Chagas' disease. J. Recept. Signal. Transduct. Res., 2008, 28, 375-401.
44. Wu, Y.; Li, M.T.; Zhao, Y.; Feng, S.; Su, L.; Dong, Y. The clinical significance of autoantibodies against acetylcholine muscarinic 3 receptor in primary Sjögren's syndrome. Zhonghua Nei Ke Za Zhi., 2008, 47, 563-565.